HCW BiologicsHCWB -4.06%47 Return-on-Tangible-Equity is 325.74% as of Mar. 2026. GuruFocus rates HCWB with a GF Score™ of 47/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,201 Biotechnology companies, HCW Biologics ranks worse than 83263.86% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. HCW Biologics's annualized net income for the quarter that ended in Mar. 2026 was $13.89 Mil. HCW Biologics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $4.26 Mil. Therefore, HCW Biologics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 325.74%.
The historical rank and industry rank for HCW Biologics's Return-on-Tangible-Equity or its related term are showing as below:
HCWB's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.4 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
HCW Biologics Return-on-Tangible-Equity Related Terms
HCW Biologics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs KAPA, IMNN, MTVA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, HCW Biologics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 325.74% mean?
HCW Biologics (HCWB) has a Return-on-Tangible-Equity of 325.74% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #999999 out of 1201 companies in the Biotechnology industry.
Is HCW Biologics' Return-on-Tangible-Equity too high?
HCW Biologics' current Return-on-Tangible-Equity is 325.74%. Based on the distribution chart, HCW Biologics ranks #999999 out of 1201 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Return-on-Tangible-Equity compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #999999 out of 1201 companies for Return-on-Tangible-Equity. This places HCW Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on HCW Biologics and its competitors. HCW Biologics's current Return-on-Tangible-Equity is 325.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $4.99 — trading 31.6% below its estimated fair value. The current Return-on-Tangible-Equity is 325.74%. HCW Biologics' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Return-on-Tangible-Equity is 325.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $4.99 is trading 31.6% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Return-on-Tangible-Equity: 325.74%
GF Value™: $7.29 vs. price of $4.99 (31.6% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
47GF Score
Get the complete analysis for HCWB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
